TOVX (Theriva Biologics) Tariff Resilience Score: 7/10 (As of Jul. 07, 2026)


TOVX Theriva Biologics Inc TOVX
24 GF Score
Price $0.25
! 3 Warning Signs
View Full Analysis

What is Theriva Biologics Tariff Resilience Score?

Theriva Biologics TOVX 24 Tariff Resilience Score is 7 as of Jul. 07, 2026. GuruFocus rates TOVX with a GF Score™ of 24/100. The stock has 3 warning signs investors should review. Among 1,368 Biotechnology companies, Theriva Biologics ranks better than 90.35% on this metric.

Theriva Biologics has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Theriva Biologics has Theriva Biologics primarily operates in the biotech sector, which is less affected by tariffs. Its supply chain is not heavily reliant on international components, and its market is largely domestic. Historical tariff changes have had minimal impact, and the company can leverage alternative suppliers if needed.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Theriva Biologics might have Highly Resilient.

Theriva Biologics  (AMEX:TOVX) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Theriva Biologics Tariff Resilience Score Related Terms

TOVX vs OSRH, PBM, PHIO: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Theriva Biologics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Theriva Biologics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theriva Biologics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Theriva Biologics's Tariff Resilience Score falls into.


TOVX
24GF Score
Theriva Biologics Inc TOVX
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Theriva Biologics (TOVX) has a Tariff Resilience Score of 7 as of Jul. 07, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Theriva Biologics ranks #132 out of 1368 companies in the Biotechnology industry, placing it in the top 9.6%.
Is Theriva Biologics' Tariff Resilience Score too high?
Theriva Biologics' current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. Theriva Biologics' value of 7 is 75% above this industry median. Based on the distribution chart, Theriva Biologics ranks #132 out of 1368 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Theriva Biologics has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Theriva Biologics' Tariff Resilience Score compare to OSRH and PBM?
According to the Biotechnology industry distribution chart, Theriva Biologics ranks #132 out of 1368 companies for Tariff Resilience Score. This places Theriva Biologics in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Theriva Biologics' value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,368 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Theriva Biologics's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Theriva Biologics's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theriva Biologics stock overvalued right now?
Theriva Biologics (TOVX) has a current Tariff Resilience Score of 7. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. Theriva Biologics' overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Theriva Biologics (TOVX), the current Tariff Resilience Score is 7 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Theriva Biologics Business Description

Address 9605 Medical Center Drive, Suite 270, Rockville, MD, USA, 20850
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.
24GF Score

Get the complete analysis for TOVX

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.25
Price